<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100890">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791127</url>
  </required_header>
  <id_info>
    <org_study_id>G110221</org_study_id>
    <nct_id>NCT01791127</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the Siello S Pacing Lead</brief_title>
  <acronym>SIELLO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the SIELLO study is to demonstrate the safety and effectiveness of the
      BIOTRONIK Siello S pacing lead.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>12 Month Adverse Event-Free Rate for Siello Leads Implanted in the Atrium</measure>
    <time_frame>12 Months</time_frame>
    <description>The percentage of participants at 12 months post-implant free from primary endpoint 1 adverse events adjudicated as related to the Siello lead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 Month Adverse Event-Free Rate for Siello Leads Implanted in the Ventricle</measure>
    <time_frame>12 Months</time_frame>
    <description>The percentage of participants at 12 months post-implant free from primary endpoint 2 adverse events adjudicated as related to the Siello lead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 Month Rate of Successful Sensing and Pacing of the Implanted System Including 1 or 2 Siello Leads</measure>
    <time_frame>12 Months</time_frame>
    <description>The rate of successful sensing and pacing is determined by the percentage of participants at 12 months post-implant free from unresolved primary endpoint 3 adverse events adjudicated as either 'lead undersensing or loss of sensing' or 'intermittent capture, no lead capture' and also adjudicated as related to the Siello lead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5 Year Adverse Event-Free Rate for Siello Leads Implanted in the Ventricle</measure>
    <time_frame>5 Years</time_frame>
    <description>The percentage of participants at 5 years post-implant free from primary endpoint 4 adverse events adjudicated as related to the Siello lead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5 Year Individual Adverse Event Rate for Siello Leads Implanted in the Ventricle</measure>
    <time_frame>5 Years</time_frame>
    <description>The percentage of participants at 5 years post-implant experiencing each individual type of primary endpoint 4 adverse event adjudicated as related to the Siello lead.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1758</enrollment>
  <condition>Safety and Effectiveness of the Siello S Lead</condition>
  <arm_group>
    <arm_group_label>Pacemaker Therapy</arm_group_label>
    <description>Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>market-released BIOTRONIK pacemaker system including one or two Siello S leads.</intervention_name>
    <arm_group_label>Pacemaker Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients selected for participation should be from the investigators' general patient
        population according to the inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Candidate for de novo implantation of a BIOTRONIK pacemaker system, including one or
             two Siello S leads. Candidate meets recommendation for pacemaker system implant put
             forth by guidelines of relevant professional societies.

          -  Able to understand the nature of the study and provide informed consent.

          -  Available for follow-up visits on a regular basis at the investigational site for the
             expected 5 years of follow-up.

          -  Age greater than or equal to 18 years.

        Exclusion Criteria:

          -  Enrolled in any other investigational clinical study.

          -  Currently implanted with a pacemaker or ICD device.

          -  Planned cardiac surgical procedures or interventional measures within the next 6
             months.

          -  Expected to receive a heart transplant within 1 year.

          -  Life expectancy less than 1 year.

          -  Presence of another life-threatening, underlying illness separate from their cardiac
             disorder.

          -  Pregnant at the time of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerseyville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Giardeau</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Steubenville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alice</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredricksburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cheyenne</city>
        <state>Wyoming</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 7, 2016</lastchanged_date>
  <firstreceived_date>February 12, 2013</firstreceived_date>
  <firstreceived_results_date>July 14, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pacemaker Therapy</title>
          <description>Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1758"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pre-Market Analysis</title>
              <participants_list>
                <participants group_id="P1" count="820"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1758"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-Market Study Cohort</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="820"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>12 Month Adverse Event-Free Rate for Siello Leads Implanted in the Atrium</title>
        <description>The percentage of participants at 12 months post-implant free from primary endpoint 1 adverse events adjudicated as related to the Siello lead.</description>
        <time_frame>12 Months</time_frame>
        <population>Participants with an atrial Siello lead that reached the 12-month follow-up time point, and/or experienced a primary endpoint 1 adverse event adjudicated as related to the Siello lead, at the time of the Pre-Market analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Adverse Event-Free Rate for Siello Leads Implanted in the Atrium</title>
          <description>The percentage of participants at 12 months post-implant free from primary endpoint 1 adverse events adjudicated as related to the Siello lead.</description>
          <population>Participants with an atrial Siello lead that reached the 12-month follow-up time point, and/or experienced a primary endpoint 1 adverse event adjudicated as related to the Siello lead, at the time of the Pre-Market analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>12 Month Adverse Event-Free Rate for Siello Leads Implanted in the Ventricle</title>
        <description>The percentage of participants at 12 months post-implant free from primary endpoint 2 adverse events adjudicated as related to the Siello lead.</description>
        <time_frame>12 Months</time_frame>
        <population>Participants with a ventricular Siello lead that reached the 12-month follow-up time point, and or experienced a primary endpoint 2 adverse event adjudicated as related to Siello lead, at the time of the Pre-Market analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Adverse Event-Free Rate for Siello Leads Implanted in the Ventricle</title>
          <description>The percentage of participants at 12 months post-implant free from primary endpoint 2 adverse events adjudicated as related to the Siello lead.</description>
          <population>Participants with a ventricular Siello lead that reached the 12-month follow-up time point, and or experienced a primary endpoint 2 adverse event adjudicated as related to Siello lead, at the time of the Pre-Market analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.62" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>12 Month Rate of Successful Sensing and Pacing of the Implanted System Including 1 or 2 Siello Leads</title>
        <description>The rate of successful sensing and pacing is determined by the percentage of participants at 12 months post-implant free from unresolved primary endpoint 3 adverse events adjudicated as either 'lead undersensing or loss of sensing' or 'intermittent capture, no lead capture' and also adjudicated as related to the Siello lead.</description>
        <time_frame>12 Months</time_frame>
        <population>Participants with a Siello lead that reached the 12-month follow-up time point, and/or experienced an unresolved primary endpoint 3 adverse event adjudicated as either 'lead undersensing or loss of sensing' or 'intermittent capture, no lead capture' and also adjudicated as related to the Siello lead, at the time of the Pre-Market analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pacemaker Therapy</title>
            <description>Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Rate of Successful Sensing and Pacing of the Implanted System Including 1 or 2 Siello Leads</title>
          <description>The rate of successful sensing and pacing is determined by the percentage of participants at 12 months post-implant free from unresolved primary endpoint 3 adverse events adjudicated as either 'lead undersensing or loss of sensing' or 'intermittent capture, no lead capture' and also adjudicated as related to the Siello lead.</description>
          <population>Participants with a Siello lead that reached the 12-month follow-up time point, and/or experienced an unresolved primary endpoint 3 adverse event adjudicated as either 'lead undersensing or loss of sensing' or 'intermittent capture, no lead capture' and also adjudicated as related to the Siello lead, at the time of the Pre-Market analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>5 Year Adverse Event-Free Rate for Siello Leads Implanted in the Ventricle</title>
        <description>The percentage of participants at 5 years post-implant free from primary endpoint 4 adverse events adjudicated as related to the Siello lead.</description>
        <time_frame>5 Years</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>5 Year Individual Adverse Event Rate for Siello Leads Implanted in the Ventricle</title>
        <description>The percentage of participants at 5 years post-implant experiencing each individual type of primary endpoint 4 adverse event adjudicated as related to the Siello lead.</description>
        <time_frame>5 Years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study duration from date of implant to the date of data cutoff for the Pre-Market analysis</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pre-Market Study Cohort</title>
          <description>The total number of subjects includes all subjects from the Pre-Market Study cohort who experienced any adverse event and/or reached the 12-month follow-up time point.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Lead dislodgement (Possibly related to RA Siello lead)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead dislodgement (Possibly related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Cardiac perforation associated with the lead (Possibly related to RA Siello lead)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Cardiac perforation associated with the lead (Possibly related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead dislodgement (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation (Related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>High pacing threshold (Related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Intermittent capture, no lead capture (Related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead impedance out of range, high impedance (Possibly related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead undersensing or loss of sensing (Possibly related to RA Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Twiddler's syndrome (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Coincidental finding of endocarditis after PPM placement (Unknown relation to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pocket pain (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Hematoma (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Damage to lead during procedure (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Inability to place lead (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Loose set-screw (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead dislodgement during Afib ablation (Unknown relation to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead dislodgement during a procedure (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead reversed in header (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Other procedure related (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous occlusion (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High pacing threshold (Possibly related to RA Siello lead)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead undersensing or loss of sensing (Possibly related to RA Siello lead)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>High pacing threshold (Possibly related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>High pacing threshold (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead undersensing or loss of sensing (Possibly related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead dislodgement (Possibly related to RA Siello lead)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation (Possibly related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>High pacing threshold (Related to RV Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Intermittent capture, no lead capture (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead dislodgement (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Lead impedance out of range, high impedance (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Other LV lead related (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Pocket pain (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Lead dislodgement during a procedure (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
              <event>
                <sub_title>Other procedure related (Unrelated to Siello lead)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Studies Engineer</name_or_title>
      <organization>BIOTRONIK, INC.</organization>
      <phone>503-451-8062</phone>
      <email>jacob.hicks@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
